Press Releases

May 15, 2021
Sydnexis Completes Enrollment in Phase 3 Clinical Trial
See more at ClinicalTrials.gov.
Read More
April 10, 2021
Sydnexis Executes Exclusive License with Santen
Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101.
Read More
August 10, 2021
Sydnexis Secures $45 Million Series B
Financing Led by Visionary Ventures and Bluestem Capital
Read More
January 27, 2020
Sydnexis Joins the Board of GMAC
GMAC’s mission is to promote public awareness of childhood myopia as a treatable disease
Read More
May 2, 2019
Sydnexis Announces First Patients in Phase 3 Clinical Trial
Announcing the Enrollment of First Patients in Phase 3 Myopia STAAR Study of SYD-101 in Children
Read More
Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, "cookies"). We use this data for multiple purposes, including for online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) and website analytics purposes, as well as to personalize content, save your preferences, provide social media features, and track the site’s performance, as further described in the "Cookies and similar tracking and data collection technologies" section of our Privacy Notice. We retain this data for as long as necessary to fulfill these purposes or as needed to comply with our record retention obligations. We do not sell your data, but we may disclose it to our marketing and advertising partners for purposes of online targeted advertising or for website analytics purposes. To opt out of the use or disclosure of your cookie-based personal data for online targeted advertising or for website analytics purposes, or to otherwise manage your preferences, please click on Cookie Settings below. For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit our Privacy Notice.